{
    "body": "What is the target of tanezumab?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22004765", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18505735", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24452657", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27936977", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25326242", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21130822", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23628600", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21696889", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21420111", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24830649", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24809946", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27381034", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23707270", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24691709", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21802499", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25527221", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25073573", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20942668", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23852695", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23010344", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26962464", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26940379", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25594611", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23028238", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20140821"
    ], 
    "ideal_answer": [
        "Tanezumab is a humanized monoclonal antibody against nerve growth factor."
    ], 
    "exact_answer": [
        "nerve growth factor", 
        "NGF"
    ], 
    "type": "factoid", 
    "id": "5890e163621ea6ff7e000004", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 142, 
            "text": "Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27381034", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 229, 
            "text": "OBJECTIVE: To investigate whether the effects of nerve growth factor (NGF) inhibition with tanezumab on rats with medial meniscal tear (MMT) effectively model rapidly progressive osteoarthritis (RPOA) observed in clinical trials.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27381034", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 559, 
            "offsetInEndSection": 847, 
            "text": " Current research focuses on the development of new OA drugs (such as sprifermin/recombinant human fibroblast growth factor-18, tanezumab/monoclonal antibody against \u03b2-nerve growth factor), which aims for more effectiveness and less incidence of adverse effects than the traditional ones.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26962464", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 549, 
            "offsetInEndSection": 775, 
            "text": "Areas covered: This manuscript is a review that examines both the pharmacological properties and clinical studies of tanezumab, the most widely studied antibody to NGF, for management of osteoarthritis (OA) and low back pain. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27936977", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 135, 
            "text": "OBJECTIVE: Evaluate efficacy and safety of tanezumab, a humanized monoclonal antibody against nerve growth factor, in neuropathic pain.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25594611", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 696, 
            "offsetInEndSection": 852, 
            "text": "In preclinical studies, tanezumab, and its murine precursor muMab-911, effectively targeted the NGF pathway in various chronic and inflammatory pain models.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20140821", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 514, 
            "offsetInEndSection": 696, 
            "text": "Tanezumab (RN-624), a first-in-class recombinant humanized mAb targeting NGF, is being developed by Pfizer Inc for the potential treatment of pain associated with several conditions.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20140821", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1029, 
            "offsetInEndSection": 1343, 
            "text": "Given that tanezumab is an antibody, the drug demonstrates the general advantages of this class of products (including good specificity and favorable pharmacokinetics), and also appears to be particularly well suited for targeting the chronic and inflammatory-mediating pain actions of NGF and its receptor system.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20140821", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 323, 
            "text": "In this randomized, double-blind, placebo controlled phase 2 study we investigated tanezumab, a humanized monoclonal antibody that specifically inhibits nerve growth factor as a treatment for interstitial cystitis pain.Patients with interstitial cystitis received a single intravenous dose of 200 \u03bcg/kg tanezumab or placebo", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21420111", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 78, 
            "text": "Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25073573", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 700, 
            "offsetInEndSection": 856, 
            "text": "In preclinical studies, tanezumab, and its murine precursor muMab-911, effectively targeted the NGF pathway in various chronic and inflammatory pain models.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20140821", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 517, 
            "offsetInEndSection": 699, 
            "text": "Tanezumab (RN-624), a first-in-class recombinant humanized mAb targeting NGF, is being developed by Pfizer Inc for the potential treatment of pain associated with several conditions.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20140821", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1035, 
            "offsetInEndSection": 1350, 
            "text": "Given that tanezumab is an antibody, the drug demonstrates the general advantages of this class of products (including good specificity and favorable pharmacokinetics), and also appears to be particularly well suited for targeting the chronic and inflammatory-mediating pain actions of NGF and its receptor system..", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20140821", 
            "endSection": "abstract"
        }
    ]
}